Does the bisphosphonate olpadronate inhibit skeletal prostate cancer progression in a green fluorescent protein nude mouse model?
The serum calcium, parathyroid hormone-related protein, and osteoprotegerin levels were significantly correlated with GFP area and X-ray scores. Treatment with olpadronate reduced tumor growth in the bone measured by GFP and X-ray imaging procedures. Imaging of GFP expression enables monitoring of tumor growth in the bone and the GFP results complement the X-ray assessment of bone disease. The data in this report suggest that olpadronate has potential as an effective inhibitor of the skeletal progression of clinical prostate cancer.
Extreme obesity is not a contraindication to elective cardiac surgery. Studies stratifying the risk factors of mortality for nonelective surgery in extremely obese patients may be warranted.